Switching to Ocrelizumab From Natalizumab for RRMS Patients at Risk of Progressive Multifocal Leukoencephalopathy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Multiple Sclerosis (Houndmills, Basingstoke, England)
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Switching to Ocrelizumab in RRMS Patients at Risk of PML Previously Treated With Extended Interval Dosing of Natalizumab
Mult. Scler. 2021 Apr 01;27(5)790-794, CR Mancinelli, C Scarpazza, C Cordioli, N De Rossi, S Rasia, MV Turrini, R CapraFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.